Napo Pharmaceuticals Tells Entities How They Can Keep Getting 340B Price on Limited-Distribution Drug

Napo Pharmaceuticals has told covered entities how they can continue to buy Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs, at its 340B price.

Napo Pharmaceuticals yesterday posted a public notice to 340B covered entities about how to obtain 340B pricing on Mytesi, an antidiarrheal for patients living with HIV/AIDS who take antiretroviral drugs.

Please Login or Become a Paid

Read More »

Genentech Notifies 340B Entities of Limited Distribution of Key COVID-19 Drug

Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.

Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Merck Due to Impose 340B Pricing Policy Changes Tomorrow

Drug manufacturer Merck is scheduled tomorrow to impose restrictions on 340B discounts when entities use contract pharmacies to dispense drugs to patients.

340B hospitals are bracing for a blow tomorrow when drug manufacturer Merck imposes restrictions on 340B discounts when entities use contract pharmacies to dispense drugs to patients.

Please Login or Become a Paid Subscriber to View

Read More »

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on

Read More »

BioMarin Paying Refunds for Two Years of 340B Overcharges on Pricey Drugs

Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

Biopharmaceutical manufacturer BioMarin is giving 340B covered entities refunds for overcharges on five of its six approved medicines from Q1 2019 through Q4 2020.

 

Please Login or Become a Paid Subscriber to View this Content

Read More »

Merck Defends and Hospitals Slam the Company’s Tougher 340B Contract Pharmacy Policy

Drug manufacturer Merck is defending and hospital groups are condemning the drug company's decision to impose mandatory conditions on 340B pricing when hospitals use contract pharmacies.

Drug manufacturer Merck says it is imposing mandatory conditions on 340B pricing when hospitals use contract pharmacies due to “very low” participation in its voluntary 340B program integrity initiative.

 

Please Login or Become a Paid

Read More »

Breaking News

Breaking: Merck Will End 340B Contract Pharmacy Pricing for Hospitals That Don’t Share their Claims Data

Drug manufacturer Merck has begun informing 340B covered entities that, effective Sept. 1, it will stop providing 340B pricing to hospitals on its drugs shipped to contract pharmacies, if the hospitals do not provide their 340B claims data.

Drug manufacturer Merck has begun informing 340B covered entities that, effective Sept. 1, it will stop providing 340B pricing to hospitals that partner with 340B contract pharmacies unless the hospitals share 340B claims data with its vendor 340B ESP.

Read More »

Biopharma Company Apellis Posts 340B Limited Distribution Notice

Apellis has posted a notice on HRSA's website informing 340B entities how they can get 340B pricing on the company's new product, Empaveli, which has a REMS.

Biopharmaceutical company Apellis has announced a limited distribution plan for Empaveli (pegcetacoplan), a newly approved treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic, life-threatening blood disorder.

 

Please Login

Read More »

Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs

Boehringer Ingelheim on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals use contract pharmacies.

Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.

 

Please Login

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report